Analyst firms · Leerink Partners · BEAM

Leerink Partners BEAM price target and rating history

Beam Therapeutics Inc. (BEAM) · Health Care

Leerink Partners rates Beam Therapeutics Inc. (BEAM) Outperform with a $39 price target, as of its latest action on Nov 6, 2024. It has published 5 rating actions on BEAM since October 2021, including 1 upgrade and 1 downgrade.

Current rating
Outperform
Price target
$39
Median target, all firms
Too few
Actions on BEAM
5

Leerink Partners price target on BEAM

$121$71$2020222023202420252026
Leerink Partners price target on BEAM, each point a stated target, October 2021 to November 2024.

Every Leerink Partners rating on BEAM

Questions about Leerink Partners and BEAM

What is Leerink Partners's price target for BEAM?
Leerink Partners's latest stated price target for Beam Therapeutics Inc. (BEAM) is $39, from its action on Nov 6, 2024.
What is Leerink Partners's rating on BEAM?
Leerink Partners rates BEAM Outperform, a bullish rating, as of Nov 6, 2024.
When did Leerink Partners last change its view on BEAM?
On Nov 6, 2024, Leerink Partners upgrades to Outperform from Market Perform, price target $27 to $39.

More BEAM rating histories

All Leerink Partners ratingsBEAM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.